QuickView for Chlorotrianisene (compound)

Chlorotrisin; Rianil; Chlorotrianisene [BAN:INN]; Clorotrianiseno [INN-Spanish]; Chlortrianisoestrolum; Clorotrianisene [DCIT]; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)-; SMR000058658; Chlortrianisen; Spectrum4_000954.
show more »

Chlorotrisin; Rianil; Chlorotrianisene [BAN:INN]; Clorotrianiseno [INN-Spanish]; Chlortrianisoestrolum; Clorotrianisene [DCIT]; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris(4-methoxy)-; SMR000058658; Chlortrianisen; Spectrum4_000954; KBio2_000596; Tace (pharmaceutical); KBioGR_001568; Chlorotris(p-methoxyphenyl)ethylene; Benzene, 1,1',1''-(1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy-; Hormonisene; SPBio_000887; Chlorotrianisene; KBioSS_000596; Chlorotrianisine; Chlorotrianisene (USAN); Chlorotrianisene [Nonsteroidal oestrogens]; TACE; Clorestrolo; 4-06-00-07650 (Beilstein Handbook Reference); Merbentul; Spectrum_000136; Chlortrianisestrol; Chlortrianisene; Prestwick_22; SPBio_002713; Ethylene, chlorotris(p-methoxyphenyl)-; KBio2_005732; Ethylene, chlorotris (p-methoxyphenyl)-; Benzene, 1,1', 1''- (1-chloro-1-ethenyl-2-ylidene)tris[4-methoxy-; CAS-569-57-3; HSDB 3302; 569-57-3; NSC-10108; Prestwick1_000757; MLS000028625; Khlortrianizen; NSC10108; NCGC00016511-01; Tri-p-anisylchloroethylene; NCGC00091333-01; Chlorotrianizen; TACE (TN); KBio3_001225; Spectrum3_000343; Clorotrisin; Tris(p-methoxyphenyl)chloroethylene; KBio2_003164; Chlortrianizen; Chloortrianisestrol; Anisene; Chlorestrolo; Trianisestrol; Spectrum2_000704; CCRIS 4769; Metace; BRN 1891845; Chlorotrianisenum [INN-Latin]; CTA; D00269; Tace-Fn; Prestwick0_000757; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); Chlortrianisenum; EINECS 209-318-6
show less «

Chlorotrianisine; Chlorestrolo; Clorotrianiseno [INN-Spanish]; Chlorotrianizen; Chlortrianisoestrolum; Chlorotrianisenum [INN-Latin]; CTA; Chlortrianisestrol; Chlortrianisene; Chlortrianisen.
show more »

Chlorotrianisine; Chlorestrolo; Clorotrianiseno [INN-Spanish]; Chlorotrianizen; Chlortrianisoestrolum; Chlorotrianisenum [INN-Latin]; CTA; Chlortrianisestrol; Chlortrianisene; Chlortrianisen; Chlortrianizen; Chloortrianisestrol; Chlortrianisenum
show less «

Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of t...
show more »

Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.
show less «

Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and...
show more »

Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
show less «